Compare SHO & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | COLL |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1995 | 2015 |
| Metric | SHO | COLL |
|---|---|---|
| Price | $9.19 | $45.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.31 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 1.7M | 467.2K |
| Earning Date | 02-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.01 | ★ 1.63 |
| Revenue | ★ $937,930,000.00 | $757,067,000.00 |
| Revenue This Year | $5.61 | $26.35 |
| Revenue Next Year | $5.58 | $3.67 |
| P/E Ratio | $931.93 | ★ $28.49 |
| Revenue Growth | 3.04 | ★ 26.34 |
| 52 Week Low | $7.45 | $23.23 |
| 52 Week High | $12.27 | $50.79 |
| Indicator | SHO | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 39.60 |
| Support Level | $9.00 | $48.50 |
| Resistance Level | $9.16 | $50.79 |
| Average True Range (ATR) | 0.15 | 1.27 |
| MACD | -0.00 | -0.68 |
| Stochastic Oscillator | 70.53 | 3.32 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.